N

Nurix Therapeutics

Drug discovery targeting ubiquitin E3 ligases

Director, Quality Compliance and Supplier Quality

Regulatory & Quality (Life Sciences)Posted on Nov 5
Full-timeBrisbane, CA, USA$243.9k - $262.6k

About the Job

Requirements

  • A bachelor's degree in chemistry, pharmaceutical sciences, life sciences, engineering, or a related field is required.
  • At least 10 years of progressive Quality Assurance or Quality Compliance experience in the pharmaceutical or biopharmaceutical industry, including at least 5 years leading audit, supplier quality, or compliance programs.
  • Demonstrated experience building or managing supplier qualification and audit programs, including oversight of CDMOs, contract laboratories, and CROs.
  • Thorough working knowledge of FDA regulations (21 CFR Parts 11, 210/211, 312, and 314), 21 CFR Part 7 (recalls), and ICH guidelines (E6(R3), Q7, Q8, Q9(R1), Q10, Q11, and Q12), as well as EudraLex Volume 4 (including Chapter 7 and Annex 11), PIC/S guidance, and Regulation (EU) No 536/2014 (Clinical Trials Regulation).
  • Proven experience with product complaint handling and CAPA programs in a clinical or commercial setting.
  • Experience supporting or leading regulatory agency inspections, such as FDA, EMA, or equivalent inspections.
  • Lead auditor experience for GxP audits, both on-site and remote, with strong report-writing and observation-classification skills.
  • Ability to lead, develop, and motivate teams in a fast-paced, ambiguous environment.
  • Project management skills and ability to manage multiple high-priority deliverables simultaneously.
  • Strong verbal and written communication skills, including the ability to present complex compliance topics clearly to diverse stakeholders, including executive leadership.
  • Willingness to travel to CDMO, supplier, and laboratory sites domestically and internationally as needed; estimated travel is 10–20%.

Responsibilities

  • Provide strategic leadership for the quality compliance program, ensuring GxP compliance with FDA, ex-US regulatory authorities, and ICH guidelines across drug substance, drug product, clinical supply, and clinical activities.
  • Apply a risk-based compliance framework and ICH Q9(R1) and ICH E6(R3) quality risk management principles to assess outsourced activities and GxP operations.
  • Maintain quality metrics, KPIs, and trending for audit findings, supplier performance, complaints, and CAPA effectiveness; prepare and present data at Quality Management Review and to executive leadership.
  • Escalate significant compliance risks with clear risk assessments and recommended actions.
  • Own the internal audit program end to end, including the annual risk-based audit schedule, audit planning and scope, execution, reporting, CAPA verification, and program governance.
  • Audit internal GxP processes and systems, including deviation and CAPA management, change control, document control and records management, training, batch record and lot disposition review, data integrity, computerized systems, and clinical supply operations.
  • Track and trend audit observations to identify systemic issues; drive remediation with process owners and verify corrective and preventive action effectiveness.
  • Establish auditor qualification, training, and independence requirements; manage internal auditors and qualified third-party auditors.
  • Use audit results and trend data to prioritize quality system improvements and inform inspection readiness activities.
  • Establish, manage, and continuously improve the external GxP audit program, setting audit frequency and depth based on assessed risk.
  • Lead or coordinate on-site, remote, and hybrid audits, including for-cause and pre-qualification audits of suppliers; review audit reports, evaluate supplier responses, drive CAPA to closure, and escalate unresolved risk to Quality leadership.
  • Support mock pre-approval inspections and pre-inspection audits at CDMOs ahead of regulatory filings.
  • Coordinate with the Qualified Person or QP service provider as needed to support EU/UK clinical certification, including audit access and information requests.
  • Manage the audit calendar, audit resourcing, and budget; maintain audit reports and certificates in the eQMS.
  • Support sponsor, partner, and licensing-partner audits of the company, including response coordination and commitments tracking.
  • Own the end-to-end supplier lifecycle for GxP suppliers and service providers, including selection support, risk classification, qualification, onboarding, performance monitoring, requalification, change management, and disqualification or exit.
  • Maintain the Approved Supplier List and supplier risk register, with documented evidence for each qualification decision.
  • Provide quality input into vendor selection and contracting in partnership with CMC, Clinical Operations, Supply Chain, and Procurement.
  • Establish supplier scorecards, performance metrics, and periodic business and quality reviews; lead supplier development and improvement plans where performance falls short.
  • Extend supplier oversight to computerized systems and data-driven service providers, such as cloud/SaaS platforms and laboratory systems, including data integrity and data governance expectations consistent with EU GMP Annex 11 and FDA data integrity expectations.
  • Verify that outsourced activities are controlled so the company can demonstrate to regulators that it retains accountability for work performed on its behalf.
  • Own the product quality complaint handling program, ensuring written procedures and records meet 21 CFR § 211.198 and applicable ex-US requirements for investigational products.
  • Define intake, triage, risk classification, investigation, and closure requirements for complaints received from clinical sites, patients, distributors, CDMOs, and partners; ensure quality unit review and documented justification when no investigation is performed.
  • Ensure timely investigation, root cause analysis, and CAPA, and ensure complaint handling responsibilities and timelines are clearly defined in Quality Agreements with contract manufacturers and distributors.
  • Establish complaint trending and signal detection, and escalate adverse trends to management and, where applicable, to Regulatory Affairs, Clinical, and Pharmacovigilance/Drug Safety.
  • Own product recall, retrieval, and market action procedures for clinical and, as applicable, commercial products, aligned with FDA guidance and ex-US requirements.
  • Lead the cross-functional recall/crisis management team: determine recall need, support health hazard evaluations with Clinical, Medical, and Safety, define recall depth and strategy, and coordinate regulatory notifications and communications.
  • Plan and execute mock recalls and traceability exercises, including clinical supply retrieval from depots and investigational sites, and track lessons learned to closure.
  • Ensure recall effectiveness checks, reconciliation, and post-recall CAPA are completed and documented.
  • Lead the company-wide regulatory inspection readiness program for FDA, EMA, MHRA, and other health authority inspections, including pre-approval inspections (PAIs) and BIMO inspections.
  • Maintain the inspection management process, including front room/back room structure, storyboards, subject matter expert preparation and training, document request tracking, and daily debriefs.
  • Manage inspection observation responses, including FDA Form 483 and equivalents, commitments tracking, and follow-up to closure.
  • Conduct readiness assessments, gap analyses, and mock inspections; apply lessons from internal and external audits and publicly available enforcement trends to strengthen readiness.
  • Prepare executives and cross-functional leaders for inspection participation.
  • Establish and maintain a structured regulatory intelligence process to monitor FDA, EMA, MHRA, PIC/S, ICH, WHO, and other authorities for new and changing GxP requirements, guidance, and enforcement trends.
  • Analyze FDA Warning Letters, Form 483 observations, and inspection outcomes for industry trends relevant to the company and its suppliers, including complaint handling, data integrity, supplier oversight, and CAPA effectiveness.
  • Perform gap assessments of new requirements against current procedures; translate requirements into practical guidance, procedure updates, and training; track implementation to completion.
  • Brief Quality leadership, CMC, and Regulatory Affairs on emerging expectations and propose phase-appropriate approaches as the company moves toward commercialization.
  • Lead, develop, and mentor a team of compliance, audit, and supplier quality professionals; set clear performance expectations and build organizational capability for commercialization readiness.
  • Manage external consultants and third-party auditors, including their budget and the quality of deliverables.
  • Build relationships with internal partners in CMC, Regulatory Affairs, Clinical Operations, Supply Chain, Legal, and Pharmacovigilance.
  • Prepare and manage the compliance and supplier quality budget and resource plans.

Desired Qualifications

  • Experience in a clinical-stage biotech environment scaling quality operations through late-stage development and toward commercialization.
  • Experience with electronic QMS platforms, such as Veeva Vault QMS, and document management systems.
  • Experience with GLP and GCP supplier oversight, clinical supply chain, and GDP requirements.
  • Professional certifications such as ASQ Certified Quality Auditor (CQA), ASQ Certified Pharmaceutical GMP Professional (CPGP), or equivalent lead auditor training.
  • Experience supporting virtual or outsourced manufacturing models.

About the Company

Nurix Therapeutics

Drug discovery targeting ubiquitin E3 ligases

Nurix Therapeutics develops drugs that use the body's own protein-degradation system to treat diseases. Its core approach is to control ubiquitin E3 ligases, enzymes that tag unwanted proteins for breakdown in cells. By modulating these ligases, Nurix aims to create therapeutics, especially small-molecule immuno-oncology agents, that can selectively remove disease-related proteins in cancer and other serious conditions. The company operates by discovering and developing drug candidates and earning revenue through partnerships, licensing, and potential future sales of its medicines. Unlike many biotech firms that target single proteins, Nurix focuses on the protein-degradation pathway to influence multiple disease processes through carefully designed molecules. The goal is to bring new cancer treatments and other therapies to patients by advancing its degrader-based drugs through research, collaboration, and development toward commercial use.

Company size
201-500
Company stage
IPO
Headquarters
Brisbane, CA
Founded
2012

Recently Posted Jobs

Explore more opportunities at Nurix Therapeutics

See more jobs